PET imaging of STING expression in cancer patients
[68Ga]Ga-Sa-DABI-4 PET Imaging of Stimulator of Interferon Gene Expression in Cancer Patients
This study is testing a new imaging agent to see if it can safely help doctors visualize a specific protein in tumors of adults with cancer, which may improve cancer treatment.
Quick facts
| Phase | Early Phase 1 |
|---|---|
| Study type | Interventional |
| Enrollment | 30 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | First Affiliated Hospital of Chongqing Medical University Academic / other |
| Locations | 1 site (Chongqing, Chongqing Municipality) |
| Trial ID | NCT06419361 on ClinicalTrials.gov |
What this trial studies
This study investigates the safety and effectiveness of a novel 68Ga-labeled agonist, [68Ga]Ga-Sa-DABI-4, for noninvasive positron emission tomography (PET) imaging of the stimulator of interferon gene (STING) expression in tumors. By monitoring STING expression, the study aims to enhance the understanding of STING therapy in cancer treatment. Participants will include adults with suspected or diagnosed malignant diseases, and the study will assess the biodistribution of the imaging agent in the tumor microenvironment.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older with suspected or newly diagnosed malignant diseases.
Not a fit: Patients with non-malignant diseases or those who are pregnant will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could improve the monitoring and treatment of cancer by providing a new method for imaging STING expression.
How similar studies have performed: While the specific approach of using [68Ga]Ga-Sa-DABI-4 for PET imaging of STING expression is novel, similar imaging techniques have shown promise in other cancer studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. At least 18 years of age. 2. Signed informed consent. 3. Patients with suspected or newly diagnosed or previously malignant disease. Exclusion Criteria: 1. Patients with non-malignant disease. 2. Patients with pregnancy. 3. The inability or unwillingness of the research participant, parent or legal representative to provide written informed consent. 4. Known or expected hypersensitivity to \[68Ga\]Ga-Sa-DABI-4 or any of its components. 5. Any serious medical condition or extenuating circumstance which the investigator feels may interfere with the procedures or evaluations of the study.
Where this trial is running
Chongqing, Chongqing Municipality
- The First Affiliated Hospital of Chongqing Medical University — Chongqing, Chongqing Municipality, China (Recruiting)
Study contacts
- Study coordinator: Xiaoyang Zhang, PhD
- Email: zhangxy@mail.bnu.edu.cn
- Phone: 023-89011755
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.